Eesti - eesti - Ravimiamet

merck sharp & dohme b.v. - beetametasoon+salitsüülhape - salv - 0,5mg+30mg 1g 20g 1tk; 0,5mg+30mg 1g 30g 1tk

Eesti - eesti - Ravimiamet

merck sharp & dohme b.v. - mometasoon+salitsüülhape - salv - 1mg+50mg 1g 50g 1tk; 1mg+50mg 1g 15g 1tk

Eesti - eesti - Ravimiamet

almirall hermal gmbh - fluorouratsiil+salitsüülhape - nahalahus - 5mg+100mg 1g 25ml 1tk

Eesti - eesti - Ravimiamet

dr. august wolff gmbh & co. kg arzneimittel - prednisoloon+salitsüülhape - nahalahus - 0,2%+0,4% 100ml 1tk

Eesti - eesti - Ravimiamet

lex ano uab - beetametasoon+salitsüülhape - nahalahus - 0,5mg+20mg 1g 30ml 1tk

Eesti - eesti - Ravimiamet

ideal trade links uab - beetametasoon+salitsüülhape - nahalahus - 0,5mg+20mg 1g 30ml 2tk; 0,5mg+20mg 1g 30ml 1tk

Eesti - eesti - Ravimiamet

ideal trade links uab - prednisoloon+salitsüülhape - nahalahus - 0,2%+0,4% 100ml 2tk; 0,2%+0,4% 100ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

eurocept international b. v. - para-aminosalitsüülhape - tuberkuloos - antimükobakterid - granupas on näidustatud kasutamiseks täiskasvanutel ja lastel alates 28 päeva vanuses multiresistentse tuberkuloosi võimaldatava raviskeemi osana ja vanemate kui efektiivset raviskeemi ole võimalik põhjustel resistentsuse või talutavuse (vt lõik 4. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Eesti - eesti - Ravimiamet

grindeks as - atsetüülsalitsüülhape - tablett - 500mg 50tk; 500mg 20tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - rivaroksabaan - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombootilised ained - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.